Cite
HARVARD Citation
Gandhi, S. et al. (n.d.). 320 Phase IIa study of alpha-DC1 vaccine against HER2/HER3, chemokine modulation regimen and pembrolizumab in patients with asymptomatic brain metastasis from triple negative or HER2+ breast cancer. Journal for immunotherapy of cancer. p. A346. [Online].